McKesson Corporation (NYSE:MCK) is favored by analysts for its strong performance and increased EPS guidance. The company's recent acquisition in oncology care reflects its commitment to growth. However, cautious optimism prevails as Wells Fargo believes the stock is currently fairly valued.